Objective
The human immune system controls the efficiency to respond to infections and eliminate aberrant cells, such as cancer cells. Immune function depends on the balanced contribution of many genes, encoding for receptors, cytokines, cell signalling molecules and transcription factors and are modulated by a wide range of environmental and epigenetic factors. Monogenic mutations for immune-related genes, also known as Inborn Errors of Immunity (IEI), provide unique examples for understanding immune fitness. IEI, individually considered as rare diseases, constitute a group of >400 immune disorders with a combined prevalence similar to leukemias (1/1,000-1/5,000). For a given mutated gene, IEI patients can display a wide range of phenotypic expressivity (from asymptomatic to severely impaired) and different responses to treatments. Therefore, there is an unmet need to address the wide underlying impact of IEI. Previous EU consortia have not addressed these questions in full. It is therefore needed a new generation of researchers, equipped with a complete set of scientific, technological and strategic skills; and a wide vision to face the outstanding challenges in the IEI field. To this end, the IMMERGE MSCA DN combines the talent of leaders from different clinical and basic research and biotech environments to train 11 doctoral candidates. Through our research activity and training activities, we will address key challenges in the field: 1) To assess the functional impact of IEI in different immune cell types through single cell and bulk multiomics. 2) To develop computational tools for dissecting the altered cellular pathways underlying specific IEI. 3) To genetically correct or model IEI and develop pre-clinical models. With our strategy, IMMERGE will generate an outstanding network of professionals able to develop impactful studies that will change the field, generate tools for personalised medicine and generate awareness in the society and influence policy makers.
Fields of science
- natural sciencesbiological sciencescell biologycell signaling
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicineimmunology
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesclinical medicineoncologyleukemia
Keywords
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral NetworksCoordinator
08916 Badalona
Spain
See on map
Participants (7)
75794 Paris
See on map
79106 Freiburg
See on map
20132 Milano
See on map
69117 Heidelberg
See on map
91120 Jerusalem
See on map
08950 ESPLUGUES DEL LLOBREGAT
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20122 MILANO
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (18)
6500 Bellinzona
See on map
08007 Barcelona
See on map
CB2 1TN Cambridge
See on map
79098 Freiburg
See on map
20132 Milano
See on map
91904 Jerusalem
See on map
08002 Barcelona
See on map
38122 Trento
See on map
6900 Lugano
See on map
08021 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
82152 Planegg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28002 MADRID
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
751 83 Uppsala
See on map
74909 Meckesheim
See on map
83530 Schnaitsee
See on map
91120 Jerusalem
See on map
CB10 1SA SAFFRON WALDEN
See on map
13284 Marseille
See on map